Drug Safety

, Volume 33, Issue 2, pp 147–161 | Cite as

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease

Meta-Analysis of Randomized Controlled Trials
Original Research Article


Background: Dopamine agonists have a well established role in the treatment of Parkinson’s disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.

Objective: The present study evaluated the tolerability and safety of ropinirole against those of other dopamine agonists (bromocriptine, cabergoline, pramipexole, rotigotine, pergolide) and placebo in monotherapy and adjuvant therapy with levodopa in the treatment of Parkinson’s disease, as reported in the peer reviewed medical literature.

Methods: A systematic review of the medical literature was carried out for relevant English language articles in the MEDLINE database and Cochrane Library from January 1975 to November 2008. The searches were limited to either double-blind clinical trials or randomized clinical trials that included both patients with early Parkinson’s disease receiving dopamine agonist monotherapy, and patients at a later stage on combined treatment with levodopa. The Cochrane Collaboration guidelines were followed and the following data were extracted from each study: identifier (title and bibliographical reference), classification of the quality of the evidence (Jadad criteria), type and design of the study, number of patients, patient demographics (average age, sex), Parkinson’s disease stage (Hoehn and Yahr Scale), treatment (monotherapy or adjuvant to levodopa), drugs used (including dosage and duration), study objective (safety or tolerability), method of evaluation of results, randomization and blinding, and description of all the adverse events in all treatment groups. A meta-analysis was performed, calculating relative risks (RRs) and confidence intervals for the 12 most relevant adverse events. On the basis of incidence and clinical importance criteria, the final selection of 12 adverse events was made by consensus between the investigators.

Results: Forty randomized clinical trials were included. Direct comparison of ropinirole with bromocriptine showed a lower RR of constipation for ropinirole (0.55 [95% CI 0.35, 0.89]), while the direct comparison with levodopa showed a lower RR of dyskinesia for ropinirole (0.25 [95% CI 0.09, 0.71]); no significant differences for either dyskinesia or constipation were found when a direct comparison of ropinirole and rotigotine was made. For nausea, ropinirole, pergolide and rotigotine versus placebo all demonstrated similar RRs (2.25 [95% CI 1.85, 2.74]; 2.28 [95% CI 1.54, 3.37]; and 2.08 [95% CI 1.30, 3.34], respectively). On indirect comparison of ropinirole with pramipexole, ropinirole showed a higher RR for nausea (2.25 [95% CI 1.85, 2.74] vs 1.48 [95% CI 1.24, 1.76]), dizziness (1.87 [95% CI 1.48, 2.37] vs 1.20 [95% CI 1.01, 1.43]), somnolence (2.45 [95% CI 1.30, 4.61] vs 1.68 [95% CI 1.25, 2.25]), and dyskinesia (2.71 [95% CI 1.74, 4.21] vs 2.27 [95% CI 1.58, 3.27]). Pramipexole (3.36 [95% CI 2.41, 4.68], pergolide (4.80 [95% CI 2.24, 10.29]), ropinirole (2.84 [95% CI 1.34, 5.99]), and rotigotine (4.02 [95% CI 1.23, 13.11]) all had a higher RR of hallucinations compared with placebo. Pramipexole also showed a higher RR of confusion (2.64 [95% CI 1.18, 5.91]) and constipation (2.23 [95% CI 1.53, 3.25]) compared with placebo.

Conclusions: In all the included studies, dopamine agonists, including ropinirole, exhibited a higher incidence of adverse events than placebo. Ropinirole showed an adverse event profile similar to other dopamine agonists. Consideration of the clinical characteristics of each patient and the differences in the incidence of adverse events related to each dopamine agonist, may help to optimize the dopamine agonist therapy.

Supplementary material

40264_2012_33020147_MOESM1_ESM.pdf (112 kb)
Supplementary material, approximately 115 KB.


  1. 1.
    Lambert D, Waters CH, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging 2000 Jan; 16(1): 55–65PubMedCrossRefGoogle Scholar
  2. 2.
    Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Transm Suppl 1995; 45: 213–24PubMedGoogle Scholar
  3. 3.
    Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson’s disease. Am J Health Syst Pharm 1999 Feb 1; 56(3): 217–24PubMedGoogle Scholar
  4. 4.
    Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997 May–Jun; 19(3): 559–69, discussion 38–9PubMedCrossRefGoogle Scholar
  5. 5.
    Delgado M, Domenench J. Revisión sistematica de metaa-nálisis. 7th ed. Madrid: Diseño de Estudios Sanitarios, 2002Google Scholar
  6. 6.
    Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson’s disease. Expert Opin Investig Drugs 2003 Aug; 12(8): 1335–52PubMedCrossRefGoogle Scholar
  7. 7.
    Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Saf 2003; 26(6): 439–44PubMedCrossRefGoogle Scholar
  8. 8.
    Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 1998 Jan; 13(1): 46–51PubMedCrossRefGoogle Scholar
  9. 9.
    Jost WH. Ropinirole: current status of the studies. J Neurol 2004 Sep; 251 Suppl. 6: VI/13-8Google Scholar
  10. 10.
    Anderson P. Cochrane reviewer’s handbook 4.2.2. Chichester: The Cochrane Library, 2004Google Scholar
  11. 11.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 Feb; 17(1): 1–12PubMedCrossRefGoogle Scholar
  12. 12.
    Navan P, Findley LJ, Jeffs JA, et al. Randomized, doubleblind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov Disord 2003 Nov; 18(11): 1324–31PubMedCrossRefGoogle Scholar
  13. 13.
    Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromo-criptine Study Group. Neurology 1997 Oct; 49(4): 1060–5PubMedCrossRefGoogle Scholar
  14. 14.
    Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: STRONG study. Mov Disord 2007 Oct 15; 22(13): 1860–5PubMedCrossRefGoogle Scholar
  15. 15.
    Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord 2003 Oct; 18(10): 1149–56PubMedCrossRefGoogle Scholar
  16. 16.
    Higgins JPT. Cochrane handbook for systematic reviews of interventions. Version 5.0.1. The Cochrane Collaboration, 2008 [online] Available from URL: http://www.cochrane-handbook.org [Accessed 2009 Dec 10]
  17. 17.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6; 327(7414): 557–60PubMedCrossRefGoogle Scholar
  18. 18.
    Parlodel: summary of product characteristics. Basilea: Novartis, 2003 [online]. Available from URL: http://www.pharma.us.novartis.com/products/name/parlodel.jsp [Accessed 2010 Jan 5]
  19. 19.
    Sogilen: summary of product characteristics. New York: Pfizer, 2005 [online]. Available from URL: http://www.pfizer.es/para/profesionales_sanitarios/login.html?ReturnUrl=/para/profesionales_sanitarios/medicamentos/sogilen.html [Accessed 2007 Dec 18]
  20. 20.
    Mirapex: summary of product characteristics. Ingelheim: Boehringer, 2003 [online]. Available from URL: http://www.mirapex.com/pd/ [Accessed 2010 Jan 6]
  21. 21.
    Requip: summary of product characteristics. London: GlaxoSmithKline, 2002 [online]. Available from URL: http://www.gsk.com/products/prescription-medicines/requip.htm [Accessed 2010 Jan 5]
  22. 22.
    Neupro: summary of product characteristics. Monheim: Schwartz Pharma, 2006 [online]. Available from URL: http://www.ucb.com/products/product-list/cns/neupro [Accessed 2010 Jan 5]
  23. 23.
    Pergolide: summary of product characteristics. Indianapolis (IN): Lilly, 2004 [online]. Available from URL: http://www.pharken.com/index.jsp [Accessed 2007 Dec 18]
  24. 24.
    Barone P, Lamb J, Ellis A, et al. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson’s disease. Mov Disord 2007 Mar 15; 22(4): 483–9PubMedCrossRefGoogle Scholar
  25. 25.
    Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa. J Neural Transm 2002 Apr; 109(4): 489–502PubMedCrossRefGoogle Scholar
  26. 26.
    Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007 Dec; 22(16): 2398–404PubMedCrossRefGoogle Scholar
  27. 27.
    Im JH, Ha JH, Cho IS, et al. Ropinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: a 16-week bromocriptine controlled study. J Neurol 2003 Jan; 250(1): 90–6PubMedCrossRefGoogle Scholar
  28. 28.
    Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study Group. Neurology 1999 Jul 22; 53(2): 364–70PubMedCrossRefGoogle Scholar
  29. 29.
    Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 1998 Oct; 51(4): 1057–62PubMedCrossRefGoogle Scholar
  30. 30.
    Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998 Jan; 13(1): 39–45PubMedCrossRefGoogle Scholar
  31. 31.
    Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003 Jul; 54(1): 93–101PubMedCrossRefGoogle Scholar
  32. 32.
    Singer C, Lamb J, Ellis A, et al. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson’s disease. Mov Disord 2007 Mar 15; 22(4): 476–82PubMedCrossRefGoogle Scholar
  33. 33.
    Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson’s disease. Neurology 1985 Feb; 35(2): 199–206PubMedCrossRefGoogle Scholar
  34. 34.
    Möller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord 2005 May; 20(5): 602–10PubMedCrossRefGoogle Scholar
  35. 35.
    Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007 May; 64(5): 676–82PubMedCrossRefGoogle Scholar
  36. 36.
    LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study. Neurology 2007 Apr 17; 68(16): 1262–7PubMedCrossRefGoogle Scholar
  37. 37.
    The Parkinson Study Group. Controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003 Dec; 60(12): 1721–8CrossRefGoogle Scholar
  38. 38.
    Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 Jun; 6(6): 513–20PubMedCrossRefGoogle Scholar
  39. 39.
    Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 Jan 23; 68(4): 272–6PubMedCrossRefGoogle Scholar
  40. 40.
    Shannon KM, Bennett Jr JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 1997 Sep; 49(3): 724–8PubMedCrossRefGoogle Scholar
  41. 41.
    Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997 Jul 9; 278(2): 125–30CrossRefGoogle Scholar
  42. 42.
    Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol 2007 Mar–Apr; 30(2): 72–85CrossRefGoogle Scholar
  43. 43.
    Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999 Apr; 66(4): 436–41PubMedCrossRefGoogle Scholar
  44. 44.
    Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997 Jul; 49(1): 162–8PubMedCrossRefGoogle Scholar
  45. 45.
    Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson’s disease. Eur J Neurol 1998 May; 5(3): 235–42PubMedCrossRefGoogle Scholar
  46. 46.
    Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine on parkinsonism: a nation-wide collaborative double-blind study. Acta Neurol Scand 1985 Aug; 72(2): 157–70PubMedCrossRefGoogle Scholar
  47. 47.
    Ahlskog JE, Wright KF, Muenter MD, et al. Adjunctive cabergoline therapy of Parkinson’s disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996 Jun; 19(3): 202–12PubMedCrossRefGoogle Scholar
  48. 48.
    Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in 161 the treatment of Parkinson’s disease. Neurology 1996 Apr; 46(4): 1062–5PubMedCrossRefGoogle Scholar
  49. 49.
    Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996 Jan; 243(1): 68–72PubMedCrossRefGoogle Scholar
  50. 50.
    Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopa-minergic therapy in Parkinson’s disease. Clin Neuro-pharmacol 1998 Mar–Apr; 21(2): 101–7Google Scholar
  51. 51.
    Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996 Jun; 19(3): 234–45PubMedCrossRefGoogle Scholar
  52. 52.
    Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson’s disease. Clin Neuropharmacol 1995 Aug; 18(4): 338–47PubMedCrossRefGoogle Scholar
  53. 53.
    Ahlskog JE, Muenter MD. Treatment of Parkinson’s disease with pergolide: a double-blind study. Mayo Clin Proc 1988 Oct; 63(10): 969–78PubMedCrossRefGoogle Scholar
  54. 54.
    Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999 Aug 11; 53(3): 573–9PubMedCrossRefGoogle Scholar
  55. 55.
    Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 1994 Jan; 9(1): 40–7PubMedCrossRefGoogle Scholar
  56. 56.
    Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 1997 Aug; 49(2): 393–9PubMedCrossRefGoogle Scholar
  57. 57.
    Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002 Jun; 72(6): 713–20PubMedCrossRefGoogle Scholar
  58. 58.
    Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease. J Neural Transm Suppl 1995; 45: 225–30PubMedGoogle Scholar
  59. 59.
    Wong KS, Lu CS, Shan DE, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. J Neurol Sci 2003 Dec 15; 216(1): 81–7PubMedCrossRefGoogle Scholar
  60. 60.
    Horowski R, Jahnichen S, Pertz HH. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 2004 Dec; 19(12): 1523–4PubMedCrossRefGoogle Scholar
  61. 61.
    Chaudhuri KR, Dhawan V, Basu S, et al. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004 Dec; 19(12): 1522–3PubMedCrossRefGoogle Scholar
  62. 62.
    Rascol O, Pathak A, Bagheri H, et al. Dopamine agonists and fibrotic valvular heart disease: further considerations. Mov Disord 2004 Dec; 19(12): 1524–5PubMedCrossRefGoogle Scholar
  63. 63.
    Hirani N, Bayliff CC, McCormack DG. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2005 Apr; 20(4): 512–3, author reply 513PubMedCrossRefGoogle Scholar
  64. 64.
    Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 2003 Oct; 18 Suppl. 7: S16-21Google Scholar
  65. 65.
    Hauser RA, Gauger L, Anderson WM, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000 Jul; 15(4): 658–63PubMedCrossRefGoogle Scholar
  66. 66.
    Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000 May 18; 342(20): 1484–91PubMedCrossRefGoogle Scholar
  67. 67.
    Sethi KD, O’Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol 1998 Sep; 55(9): 1211–6PubMedCrossRefGoogle Scholar
  68. 68.
    Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000 Oct 18; 284(15): 1931–8CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Unit of Movement Disorders, Neurology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain
  2. 2.CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)Instituto de Salud Carlos IIIMadridSpain

Personalised recommendations